Lilly drug cuts breast cancer risk, fewer side-effects
Posted on: Monday, 17 April 2006, 13:16 CDT
WASHINGTON (Reuters) - Evista, Eli Lilly and Co's osteoporosis drug, works just as well as the older drug tamoxifen in reducing the risk of breast cancer in high-risk women, and without some of the dangerous side-effects, researchers said on Monday.
The results of the 19,000-woman Study of Tamoxifen and Raloxifene (STAR) trial show that Evista, known generically as raloxifene, is less likely to cause blood clots and uterine cancer, yet like tamoxifen lowers the risk of breast cancer by 50 percent.
Women have long been prescribed tamoxifen, sold as a generic and by AstraZeneca Plc under the brand name Nolvadex, both to treat and prevent breast cancer. Lilly said it would seek U.S. Food and Drug Administration approval to market Evista both for osteoporosis and to prevent breast cancer.
Source: REUTERS
Related Articles
- St. Louis Cancer & Breast Institute Physician Says Hormone Replacement Therapy Does Indeed Create Breast Cancer Risk
- Community Oncology Alliance Refutes NBC Nightly News Story 'Cancer Docs Profit From Chemotherapy Drugs'
- Prostate Cancer Treatment Has Health Risks
- Younger Breast Cancer Patients More at Risk: Study
- Milder types of skin cancer may raise melanoma risk
- U-Turn Allows Cancer Patients to Get New Drug
- HEALTH: 10 FACTS YOU SHOULD KNOW ABOUT BEATING BREAST CANCER ; Breast Cancer is Estimated to Affect One in Nine Women in Britain. Luckily, There Have Been Huge Developments in Treatments Available Heres a Look at What the Future Holds for the Fight Again
- What About Breast Cancer and Cardiovascular Disease Risks With the Best Treatments During the Climacterium and Beyond
- Acapodene(R) Reduction of Prostate Cancer Incidence in High Risk Men Highlighted at Press Briefing at Annual Meeting of American Society of Clinical Oncology
- Tamoxifen Ups Risk of Uterine Sarcoma
 |
 |
User Comments (0)
RSS Feeds